The month of March will bring eight more chances for the US FDA to approve novel drugs and biologics, potentially providing a corrective to 2024’s slow start for innovative approvals.
The number of user fee goal dates for novel agents on the FDA’s March calendar already outweighs the new molecular entity and novel biologic decisions in January and February combined, the Pink Sheet’s US FDA Performance Tracker
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?